Study finds that COVID-19 can cause long term alterations on corneal endothelial cells

News
Article

Specular microscopy showed that the ocular symptoms in the patients who had had COVID-19 included conjunctival hyperemia, foreign body sensation, tearing, ocular secretion, and chemosis.

Woman rubbing both her eyes Image credit: AdobeStock/Parkin

Image credit: AdobeStock/Parkin

A team of Turkish investigators lead by Oğuzhan Kılıçarslan, FEBO, FICO, MD, reported that COVID-19 affected the corneal endothelial cell morphology in patients with ocular symptoms.1 Kılıçarslan is from the Department of Ophthalmology, Ayancık State Hospital, Sinop, Turkey.

They conducted a study in which they investigated the long-term effects of the virus on corneal endothelial cell morphology in patients with ocular symptoms to assess possible corneal involvement in patients who recovered from the disease.

The study was comprised of 2 groups, the COVID-19 group of patients who had been diagnosed and treated at Istanbul University Cerrahpasa Medical Faculty with confirmed SARS-CoV-2 infection and ocular irritation symptoms and the control group with no ocular pathologies that included age- and sex-matched individuals.

The investigators performed noncontact specular microscopy using the center method 156 days after COVID-19 had been diagnosed to analyze the endothelial cell density (ECD), hexagonality (HEX), coefficient of variation, and central corneal thickness.

Microscopy results

A total of 54 patients who had COVID-19 and had ocular irritation and 72 controls were included.

Specular microscopy showed that the ocular symptoms in the patients who had had COVID-19 included conjunctival hyperemia, foreign body sensation, tearing, ocular secretion, and chemosis. The mean ECDs were 2,770 cells/mm2 in the COVID-19 group and 2,897 cells/mm2 in the control group; the mean HEX was 46.52 in the COVID-19 group and 58.22 ± 13.94 in the control group.

The patients who had had COVID-19 had significantly lower endothelial ECD and HEX levels than controls (p = 0.003 and p< 0.001, respectively).

Kılıçarslan and colleagues concluded, “COVID-19 can cause long-term alterations in the corneal endothelial cells, leading to decreased ECD and HEX. Future research should focus on the long-term implications of COVID-19 on the corneal health and visual outcomes.”

Reference:
  1. Kılıçarslan O, Yılmaz Çebi A, Doğan C, Arslan OS. Long-term corneal endothelial parameters of covid-19 patients with ocular surface symptoms. Cornea 2024;43:1124-1127; DOI: 10.1097/ICO.0000000000003552
Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.